Last reviewed · How we verify
NCT03379272: CONNECT
Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital
NA trial testing GOLDSTANDARD in Epilepsy. Withdrawn.
20 December 2020
Quick facts
| Lead sponsor | BioSerenity |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 20 December 2020 |
| Primary completion | 20 December 2020 |
| Estimated completion | 20 December 2020 |
Drugs / interventions tested
- GOLDSTANDARD
- NEURONAUTE
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
BioSerenity
Who can join
Adults 18 to 85, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study is designed to evaluate the performance of the Neuronaute in comparison with the gold standard EEG in patients with a regular appointment at the hospital. The design of this study is guided by two overriding factors : (i) epileptics disorders suspected or either (ii) epileptics already diagnosed. Volunteers will be asked to participate to this study. This study will enroll 35 outpatient subjects aged 18 to 85. Informed consent will be obtained from the patients, and assent from the subjects, prior to any form of assessment or intervention as part of the study. Patients will be submitted to the studied device record Neuronaute following by the gold standard EEG. A grid with all EEG activity recorded during the trial will be provided for evaluation after completion of the trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03379272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other BioSerenity trials
Trials by the same sponsor.
- NCT04875442 — Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions · NA · withdrawn
- NCT04161716 — Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH) · NA · completed
- NCT04180410 — Monitoring of Regional Lung Ventilation by Chest Electrical Impedance in the Course of Extubation · NA · unknown
- NCT03805243 — Evaluation of the Signals Electrophysiological Measured by Intelligent Textiles · NA · terminated
- NCT04069390 — evaluatioN de la perfOrMAnce De Capteurs E-textiles · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03379272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioSerenity
- Last refreshed: 11 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03379272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing